Inotuzumab (CAS 1660159-36-3) is a humanized IgG4 monoclonal antibody that targets CD22 on B cells. It inhibits tumor growth and enhances immune destruction of cancer cells. It links to the toxic agent ozogamicin to form Inotuzumab ozogamicin, an ADC that delivers cytotoxic agents directly to CD22-positive leukemia cells.
Key Features:
- Target Specificity: Binds to CD22 on B cells.
- Mechanism of Action: Inhibits tumor growth and boosts immune-mediated destruction.
- Conjugate: Linked with ozogamicin for targeted therapy.
Applications:
- Cancer Therapy: Used in treating acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma.
- Antibody-Drug Conjugates (ADCs): Used for targeted drug delivery.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
